Alitair has out-licensed two product candidates utilizing its REA platform technology, and additional product candidates are available for out-licensing, the company said.
Alitair president and CEO William Howard said the REA platform technology allows to improve upon currently available therapies and create new oral-solid formulations with less frequent dosing schedules, both of which have been shown to improve patient adherence.
"We will continue to pursue additional patent protection in the U.S. and in key markets around the world," Howard added.